Albiglutide

Tanzeum

GLP-1 Receptor Agonist GLP-1 SubQ FDA/EMA Label

Half-life

5 days

Time to Peak

3 days

Steady State

~25 days

Dose Range

30–50 mg

Frequency

Weekly

Overview

Once-weekly injectable GLP-1 receptor agonist for type 2 diabetes. Discontinued by GSK in 2018 due to commercial reasons (not safety). Historical compound retained for data completeness.

Mechanism of Action

GLP-1 receptor agonist fused to recombinant human albumin. The albumin fusion extends the half-life to ~5 days for weekly dosing.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	30–50 mg	5 days	3 days	Weekly

Storage & Handling

2-8C — Product discontinued in 2018.

Used in Regimens

Albiglutide is not currently part of any catalog regimen.

Data Sources

FDA Label Tanzeum FDA Prescribing Information (archived)

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Albiglutide with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.